Diabetic Peripheral Neuropathic Pain: Case Studies

Belgrade, Miles J.; Cole, B. Eliot; McCarberg, Bill H.; McLean, Michael J.
April 2006
Mayo Clinic Proceedings;Apr2006 Supplement, Vol. 81 Issue 4, pS26
Academic Journal
Three case reports in this article illustrate the diagnostic methods used and the treatment course encountered for many patients with diabetic peripheral neuropathic pain (DPNP). Each case addresses an aspect of DPNP: pain that appears to be refractory to initial therapy, DPNP occurring with other medical conditions, and nondiabetic neuropathy occurring in patients with diabetes mellitus. Together, these cases bring clarity to the confusing clinical experience for patients who have decreased sensation in combination with burning pain, and they apply the consensus guidelines for DPNP. Recently approved medications by the Food and Drug Administration for the treatment of DPNP offer hope for many patients whose pain was thought to be refractory to treatment.


Related Articles

  • FDA restricts rosiglitazone use.  // Endocrine Today;Oct2010, Vol. 8 Issue 10, p1 

    The article announces that the U.S. Food and Administration (FDA) will impose limits on the use of rosiglitazone to patients with type 2 diabetes who cannot control their diabetes with other medications.

  • Mixed vote on rosiglitazone. Elliot, William T. // Infectious Disease Alert;Sep2010 Supplement, p2 

    The article reports on the mixed vote result of the U.S. Food and Drug Administration (FDA) committee on the embattled diabetes drug rosiglitazone, brand name Avandia by GlaxoSmithKline, which has been under heavy scrutiny since 2007 when a study from the Cleveland Clinic linked the drug to an...

  • Diabetes drug delays stir controversy. Wechsler, Jill // Managed Healthcare Executive;Apr2009, Vol. 19 Issue 4, p6 

    The article reports on the issue regarding the latest diabetes treatment safety information required by the Food and Drug Administration (FDA) in the U.S. It mentions that FDA has been alarmed to the new diabetes treatments due to its adverse effects to the cardiovascular system and cites the...

  • Repaglinide: A new oral blood glucose-lowering agent. Cheatham, Wayman Wendell // Clinical Diabetes;1998, Vol. 16 Issue 2, p70 

    Presents information on the drug, repaglinide which is used in the treatment of type two diabetes highlighting its approval from the United Stated Food and Drug Administration. Comparison of the drug to sulfonylureas and other oral antidiabetic drugs; How the drug works; Clinical pharmacology...

  • Developments in Diabetes.  // FDA Consumer;Sep/Oct99, Vol. 33 Issue 5, p6 

    Presents articles pertaining to the important changes the treatment of diabetes in the United States saw in 1999. Decision of the Food and Drug Administration and Parke-Davis in tightening restriction on the use of Rezulin, a drug approved to treat Type II diabetes; Objective of the decision;...

  • Artificial Pancreas May Soon Be a Reality. Friedrich, M. J. // JAMA: Journal of the American Medical Association;4/15/2009, Vol. 301 Issue 15, p1525 

    The article presents an overview of research which is being conducted by U.S. scientists in an effort to develop an artificial pancreas for diabetics that will be able to use a computer algorithm to process readings from a continuous glucose monitor and direct an insulin pump to deliver insulin...

  • New insulin helps control blood glucose levels. Hitchens, Kathy // Drug Topics;7/25/2005, Vol. 149 Issue 14, p10 

    This article reports that approval of insulin detemir by the U.S. Food and Drug Administration. The approval rounds out the Novo Nordick product line for diabetes. It also adds a new tool to help patients with diabetes achieve blood glucose targets and perhaps avoid gaining weight. According to...

  • New study finds dysglycemia risk. Elliott, William T. // Infectious Disease Alert;Oct2013 Pharmacology Watch, p1 

    The article reports on a study from Taiwan which found new side effects of the antibiotic fluoroquinolones from 78,000 diabetic patients who were monitored for dysglycemia. It states that hyperglycemia risk per 1,000 patients was 6.9% for those using moxifloxacin and 1.6% for macrolides while...

  • More Side Effects of Fluoroquinolones Coming to Light. Elliott, William T. // Infectious Disease Alert;Oct2013 Pharmacology Watch, p1 

    The article reports on the warning of the U.S. Food and Drug Administration's Drug Safety Communication that the antibiotic fluoroquinolones such as ciprofloxacin, moxifloxacin, and levofloxacin may produce the risk of permanent neuropathy and as such has warned on the parenteral and oral forms...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics